The Belief Gap: Why Brilliant MedTech Innovation Fails to Win Stakeholders

In this report, Michael Fallone, President of Launch by Boyd, discusses the medical device Belief Gap — the disconnect between the quality of biomedical innovations and an entrepreneur's ability to inspire the stakeholder conviction that drives action.

Executive Summary

I talked to a somewhat frustrated MedTech CEO last week. She had recently run the gauntlet of multiple investor pitches and had failed to gain any traction over the past few months.

She told me, “Our main competitor just raised $35 million. I’m confident our solution is better. We’re farther along. I have a great team, and our IP is more defensible than theirs.”

She asked me, “What do you think? Why are we not getting traction?”

I said, “Give me your elevator pitch, then walk me through your deck.”

The answer became apparent pretty quickly.

Her quick pitch meandered, even over a short amount of time. It wasn’t clear, concise, compelling, or engaging.

The deck? A coherent strategy was missing, and before she got to slide four, investors had already checked out.

I recognized the problem because I’ve seen it over and over again.

Brilliant innovators with breakthrough technology can’t get traction. Not because the science is weak. Not because there’s no market. Not because the team can’t execute.

Because they have a Belief Gap.

Optimistic. Dedicated. Underprepared.

Every day, my team and I meet exceptional MedTech innovators. Almost invariably, they share three characteristics.

First: They’re wildly optimistic — and I mean that in the best way possible.

While most people require certainty before they’ll act, these innovators are energized by possibility itself. They look at an intractable problem and think, “We just might be able to solve this.” That orientation toward possibility is rare, valuable, and worth protecting.

Second: They’re relentless.

Years poured into R&D. The regulatory maze navigated. Clinical trials designed, funded, and executed. Technology, team, and operations continuously refined. They stay focused on what just might work long after others have walked away.

And third: They are seriously underprepared as communicators.

Despite all of that brilliance and perseverance, the quality of their innovation dramatically outweighs the quality of how they communicate it. Not just to investors — to every stakeholder who matters. The KOLs who could champion it. The experts and talent they need to attract. The partners who could scale it. The physicians who need to prescribe it. The health systems that need to adopt it.

What makes this particularly difficult — and worth understanding precisely — is that the qualities responsible for their innovation are often the same qualities undermining their communication. Their comfort with uncertainty, their excitement about possibility, that just might energy — these serve them brilliantly in the laboratory and the clinic. In a stakeholder meeting, they frequently work against them.

The result is a massive disconnect between the quality of their innovation and the quality of how that innovation is communicated. And the cost of that disconnect is far greater than most founders realize.

The Belief Gap

This disconnect has a name. We call it the Belief Gap.

The Belief Gap is the chasm between the quality of your breakthrough innovation and your ability to inspire genuine belief — the emotional conviction that drives action — in every stakeholder who matters.

The gap is not in your credentials, your data, your team, or your technology. It is in your strategy, your narrative, your messaging, and every touchpoint you put in front of stakeholders. No one is questioning your scientific credibility. The Belief Gap is a communication architecture problem, not a science problem.

You can be highly credible yet still not believable. The two are not the same thing.

When your brand lacks cohesive confidence. When your strategic narrative meanders. When your positioning is unclear. When your messaging focuses on features instead of outcomes. When your delivery lacks clarity, precision, and genuine engagement. When your materials look thrown together — stakeholders will not reach the belief state that drives action.

They won’t see why they should care. They won’t believe in you. They won’t believe you’ll succeed. So they don’t invest. They don’t adopt. They don’t prescribe. They don’t advocate. They don’t choose you.

Not because your innovation isn’t good enough. Because you haven’t cultivated and inspired belief.

A Legion of Stakeholders

You need each of your stakeholders to arrive at one thing: the genuine belief that you will deliver.

What makes MedTech uniquely demanding is the sheer breadth of that stakeholder universe. Unlike most industries, where commercial success depends on winning one or two primary audiences, MedTech founders must simultaneously earn belief across seven or eight distinct stakeholder groups — each with subsets of their own. Your success does not depend on perfecting your technology alone, though that is obviously necessary. It depends on winning every single one of those stakeholders and giving each of them every reason to believe.

Your business is rooted in undeniable facts — the science, the data, the clinical evidence. These are real and necessary. But your stakeholders make choices based on personal belief, not simply facts. Evidence informs belief. It never replaces it.

A growing body of research now classifies belief itself as a form of emotion. Philosopher Miriam Schleifer McCormick, writing in her 2025 Oxford University Press book Belief as Emotion, argues that belief is not merely shaped by emotion — belief is a type of emotion: an irreducibly blended state containing cognitive, motivational, and phenomenological elements. To believe something, on McCormick’s account, is to feel that your representation of the world is accurate. The cognitive and the emotional cannot be separated.  The implication for MedTech founders is precise and uncomfortable: if belief is emotion, then changing a stakeholder’s belief is not simply a matter of presenting stronger evidence. It requires creating the conditions for a different emotional experience. That is a fundamentally different communication challenge than the one most founders are currently solving for.  Are you doing everything you can to create and curate an emotional connection with your stakeholders — or are you only attempting to make a cognitive one?

If you can’t acknowledge the reality of personal belief as a necessary condition for your forward progress — if you can’t tap into it, if you can’t inspire it — your stakeholders will not make the choices you need them to make. Every single one of them is making a belief decision. Right now, each of them has a different threshold:

• Investors need to believe you’ll scale and win.

• KOLs need to believe enough to stake their professional reputation.

• Strategic partners need to believe you can execute at scale.

• Healthcare professionals need to believe you won’t disrupt workflow or compromise patient outcomes.

• Hospital systems need to believe you’ll improve outcomes without breaking budgets.

• Regulators need to believe you meet safety and efficacy standards.

• Payers need to believe your value justifies reimbursement.

• Even the top talent you need to realize your vision needs to believe in your future.

And right now, you may not be giving any of them enough to believe in — not because your innovation is lacking, but because your strategy, narrative, and communication aren’t yet up to the task of inspiring belief at each of those thresholds.

Just Might and Just Mighty

We see two distinct communication states in the MedTech innovation world. Just Might and Just Mighty. Understanding the difference between them is the first step toward closing your Belief Gap.

Just Might is what got you here.

It is the possibility-driven mindset that enabled you to innovate when everyone else saw too much risk. “We just might be able to solve this.” That blue-sky orientation fueled your R&D, sustained you through regulatory complexity, and kept you moving when the evidence was still accumulating. While most people require certainty before they act, Just Might thinkers are energized by possibility itself.

Just Might is your superpower as an innovator.

Just Mighty is what every stakeholder needs before they’ll commit.
Just Mighty presents the same innovation with absolute confidence, clarity, and compelling evidence. It communicates certainty, not possibility. It conveys the inevitability of success, not just the potential. It focuses on impact and outcomes, not features and mechanisms. Where Just Might says “this could work,” Just Mighty says “here is the evidence that it does, and here is why your future is better with it.”

• Total confidence, not cautious possibility

• Proven impact, not projected potential

• Concrete outcomes, not interesting mechanisms

• Inevitable success, not uncertain journey

• Absolute clarity and focus, not distractions and doubt

Just Mighty is the language of conviction — the language of belief. It is when you and your brand look, sound, and act with complete intelligence, confidence, and clarity at every touchpoint and in every communication. It is when how you communicate becomes as important as what you communicate.

What stands between Just Might and Just Mighty? The Belief Gap.

Why Credibility Does Not Equal Believability

Most MedTech founders operate on a logical assumption: if they develop a compelling solution, generate sufficient data, build a credentialed team, protect their IP, and demonstrate clinical proof of concept, stakeholders will believe. This assumption is understandable. It is also insufficient.

The research is unambiguous on this point. Nobel laureate Daniel Kahneman’s foundational work on cognition identifies two systems of thinking that operate simultaneously in every person’s mind.

System 1: Where belief forms.
System 1 is automatic, unconscious, and pattern-matching. It operates on intuition, emotion, and accumulated experience. It handles the vast majority of decisions and does so in milliseconds, well before conscious analysis begins.

System 2: Where belief is rationalized after the fact.
System 2 is slow, deliberate, and analytical. It processes complex information and applies logical scrutiny. But critically, it tends to accept the conclusions System 1 has already reached rather than rigorously correct them.

The neuroscientist Antonio Damasio arrived at a compatible finding from a different direction. His clinical research with patients who had sustained damage to the emotional processing centers of the brain revealed a striking result: these patients became incapable of making decisions at all — not poor decisions, but no decisions. Damasio concluded that emotion is not a distortion of rational judgment. It is the mechanism by which judgment becomes possible.

Taken together, Kahneman and Damasio point to the same truth: the emotional response is not secondary to the belief decision. It is the belief decision. Your stakeholder’s System 1 has rendered a verdict on your pitch within the first 30 to 90 seconds — based on emotion, intuition, and pattern recognition, not your data.

If System 1 says yes, System 2 spends the rest of the meeting building the case for “yes.” If System 1 says no, System 2 builds the case for “no.”

You can have exceptional credibility under System 2 and still lose based on System 1’s immediate response to your communication.

Strength Becomes Weakness

The relationship between expertise and communication effectiveness in MedTech is counterintuitive and worth examining closely.

The qualities that make founders exceptional at innovation actively undermine them in stakeholder communication:

• Comfort with uncertainty — which enabled breakthrough innovation — reads as risk to investors.

• Excitement about possibility — which fueled R&D — makes a hospital CFO worry about execution readiness.

• “Just might work” energy — which sustained the team through clinical trials — makes strategic partners hesitant to commit.

Each stakeholder group requires a different register. Investors need the language of returns. Physicians need clinical confidence. Health systems need workflow integration and demonstrated economic value.

What makes this particularly difficult is a pattern that deepens with expertise: the more a founder knows about what they’ve built, the more they want to explain it. Every mechanism. Every nuance. Every caveat. These caveats are scientifically honest. That is not the problem.

The problem is that to a stakeholder standing at the threshold of a belief decision — a funding decision, an adoption decision, a prescription decision — nuance reads as uncertainty. Accumulated detail reads as doubt. And doubt is the enemy of belief.

This is not an argument for oversimplification or for abandoning scientific integrity. It is an argument for precision of a different kind.

Your stakeholders aren’t evaluating your science. They’re deciding whether to believe in your future.

That decision requires a strategy and a level of communication preparation that most founders have not yet prioritized.

The Compounding Cost

The Belief Gap does not produce a single, contained failure. It compounds — each missed belief decision narrowing the options available for the next.

With investors:

Meetings go poorly, which drags out funding rounds or kills them entirely, which narrows strategic options and burns runway, which makes the next raise harder to structure and harder to win.

With strategics:

Interest stalls at the exploratory stage, which delays the partnerships that would accelerate your path to market, which hands competitors the relationships — the distribution, the validation, the scale — that should have been yours.

The science was there. The innovation was there. The team was there.

What wasn’t there was stakeholder belief.

The MedTech industry has a well-populated graveyard of companies “that just couldn’t get traction.” In most cases, the innovation was real. The Belief Gap was too wide.

The Good News: It’s Entirely Fixable

The Belief Gap is entirely fixable. It can be diminished, closed, or eliminated. And it is not nearly as difficult to address as the scientific and clinical challenges you have already overcome.

The solution is not changing your innovation, your team, or your data. The solution is strategically changing how you present what you’ve built — ensuring the quality of your communication is commensurate with the quality of your innovation. That work is systematic, strategic, and very much within reach.

One further consideration: your competitors are actively looking for every advantage they can find. Communication quality is one most of them have not yet prioritized. It is available to you now.

Three Pillars to Close the Gap

Closing the Belief Gap requires three interconnected efforts. Each builds on the one before it. The order is not arbitrary.

Pillar 1: Strategy. Strategy. Strategy.

Strategic foundation is where the work begins. This means defining every guidepost needed to navigate the journey to commercialization or exit: your market position, your competitive differentiation, your stakeholder-specific value propositions, and the narrative architecture that ties them together. The goal is a comprehensive, actionable foundation of intelligence that flexes as you progress and enables your entire organization to communicate, make decisions, and operate with absolute consistency, clarity, and confidence.

Without this foundation, stakeholder encounters default to improvisation — and improvisation is where Belief Gaps widen.

Pillar 2: Be Stakeholder-Specific.

Strategy becomes belief-inspiring communication through precise translation. Each stakeholder group has distinct concerns, distinct belief thresholds, and distinct standards of evidence. Generic messaging that attempts to speak to everyone reaches no one at the level of conviction required to act.

This pillar is where your technical brilliance is converted into belief-inspiring narrative — calibrated specifically to what each audience needs to hear in order to move from interest to conviction, from conviction to belief, from belief to action. Your innovation does not change. Your language must.

Pillar 3: Touchpoint Like You Mean It.

Strategy and messaging must become tangible in every stakeholder encounter. Your brand design, investor materials, clinical content, digital presence, conference presence — each touchpoint is either reinforcing or undermining the belief your communication is designed to create.

Stakeholders form impressions from the totality of your communication, not from any single element. The standard is simple: every touchpoint must signal the same level of excellence as your innovation. Right now, for most MedTech founders, there is a gap between those two standards. That gap creates doubt. Eliminating it is the work of this pillar.

The Transformation When You Close the Gap

The effects of closing the Belief Gap are felt across every stakeholder relationship, often quickly and sometimes dramatically.

Investors stop checking texts during your pitch and start competing for allocation. They ask “how much can we get?” instead of “should we invest at all?”

• Physicians stop saying “I’ll wait for more data” and become early adopters who bring colleagues along.

• Health systems stop saying “we need to study this further” and move from pilot to system-wide rollout.

• Strategic partners stop hedging and fully commit, integrating you into their strategic roadmaps.

• KOLs stop being cautious and become genuine assets — proactively championing your work with peers.

• Trade media take you seriously and become active partners in telling your story.

• Patients stop being unaware and start asking their physicians for you by name.

That’s when excellence finds its voice. That’s when the world doesn’t just listen — it believes, invests, adopts, prescribes, advocates, and chooses you.

The Self-Assessment

Three questions. Answer them honestly.

Question One:  Is there meaningful room to improve the clarity and quality of your strategic narrative, stakeholder messaging, and every digital and tangible touchpoint you own?

Question Two:  Are you consistently receiving polite interest rather than sincere, urgent engagement from the stakeholders who matter most?

Question Three:  Do your efforts ever feel futile — as though you’re making progress one week only to lose ground the next, without a clear explanation for why?

A yes to any of these is a signal worth taking seriously. And if you are struggling to win stakeholders despite strong technology and a clear pathway, the location of your Belief Gap is probably already clear to you.

The Choice

The Belief Gap between Just Might and Just Mighty can be eliminated or significantly diminished. The question is not whether it can be closed — the frameworks exist, the expertise exists, and the path is navigable. The question is whether you will prioritize it with the same urgency you have brought to your technology.

Will you?

Will you invest in closing this gap with the same rigor you deployed in developing your innovation and navigating your regulatory pathway? Will you make strategy and communication quality a genuine priority rather than an afterthought? Will you commit to a Just Mighty standard across every stakeholder interaction?

Without that commitment, the Belief Gap persists. Your life-changing innovation does not reach the patients whose lives depend on it. Your runway burns. Your competitors — with less impressive science but better communication — take the ground that should be yours.

But when your innovation finds its voice — when your strategy, your narrative, your brand, and every touchpoint reflect the same standard of excellence as your science — the outcome changes.

The world won’t just listen. It will believe. It will invest. It will partner. It will adopt. It will advocate.

It will choose you.

About Michael Fallone

Michael Fallone works with MedTech innovators to close the gap between the quality of their innovation and the quality of how they communicate it. Through Launch by Boyd, he provides strategy, brand development, marketing, and communications programs to MedTech innovators meet their objectives and journey towards commercialization.